Features
Get A Demo
Plans
Sign Up
Login
All Federal Grant Programs
National Center for Advancing Translational Sciences
Posted
7/24/18
Assistance Listing Number
93.350
Overview
Grant Opportunities
327
Grant Awards
1.4K
Federal Agency
National Institutes of Health
Applicant Types
Not listed
Beneficiary Types
Not listed
Additional Information
Not listed
Popular Federal Grant Opportunities
Not listed
Popular Federal Grant Awards
Not listed
Name
Description
Awardee
Assistance Type
Dollars Obligated
(Click to sort descending)
Award Date
(Click to sort descending)
Updated At
(Click to sort descending)
R43TR001286
TOOLS FOR DRUG EFFICACY STUDIES IN PERFUSED TISSUE MODELS
Lena Biosciences, Inc.
Cooperative Agreement
$325.0k
5/1/16
5/21/18
UL1TR000001
HEARTLAND INSTITUTE FOR CLINICAL AND TRANSLATIONAL RESEARCH
University Of Kansas Medical Center Research Institute, Inc.
Cooperative Agreement
$13.0m
6/1/11
3/1/18
R21TR004265
BRAIN MRI TO PRE-SYMPTOMATICALLY PREDICT SEIZURE ONSET FOR STURGE-WEBER SYNDROME - ABSTRACT STURGE-WEBER SYNDROME (SWS) IS A RARE NEUROLOGICAL DISEASE, AND ITS BIGGEST CONCERN IS NEUROCOGNITIVE IMPAIRMENTS BY SCHOOL AGE (6-10 YEARS). TO IMPROVE NEUROCOGNITIVE OUTCOMES, KENNDY KRIEGER INSTITUTE (DR. COMI, CO-PI OF THIS R21) AND BOSTON CHILDREN'S HOSPITAL (DR. PINTO, CO-PI OF THIS R21) HAVE BEEN THE LEADING OR KEY SITES IN VARIOUS CLINICAL TRIALS, TO TEST NEW TREATMENT (NCT02332655 (2014-19); NCT0304980 (2017-19); NCT04447846 (2019-21)), OR TO DEVELOP NEUROIMAGING BIOMARKERS THAT CAN SELECT AT-RISK PATIENTS (NCT01345305 (2010-2012); NCT01425944 (2010-2020); NCT04717427 (2021-2024)). HOWEVER, ALL THESE TRIALS FOCUS ON THE POST-SYMPTOMATIC PHASE - AFTER SEIZURE SYMPTOMS HAVE OCCURRED. OUR RECENT EVIDENCE SUGGESTED THAT PRE-SYMPTOMATIC TREATMENT - TREATING PATIENTS BEFORE SEIZURE SYMPTOMS OCCUR, IDEALLY BEFORE 2 YEARS OF AGE - MAY DELAY OR AVOID SEIZURE SYMPTOMS. THIS IS IMPORTANT, BECAUSE THOSE WITHOUT SEIZURE SYMPTOMS BY 2 YEARS OF AGE (10-25% OF SWS PATIENTS) OFTEN ENJOY GOOD NEUROCOGNITIVE OUTCOMES BY SCHOOL AGE. MOTIVATED BY THIS, MULTIDISCIPLINARY EXPERTS GATHERED AND REACHED A CONSENSUS IN 2018, 2019, AND 2021, CALLING FOR IMMEDIATE INVESTIGATIONS OF PRE-SYMPTOMATIC TREATMENTS. IN A TIMELY RESPONSE TO THIS CALL, KKI AND BCH, THE TWO LARGEST NATIONAL CENTERS THAT TREAT SWS PRE-SYMPTOMATICALLY, ARE PLANNING FOR A TRIAL TO COMPREHENSIVELY EVALUATE THE EFFECT OF ANTI-EPILEPSY DRUGS LEVETIRACETAM, IN TWO TREATMENT ARMS (LEVETIRACETAM WITH VERSUS WITHOUT LOW-DOSE ASPIRIN) FOR PRE-SYMPTOMATIC TREATMENT. THE BOTTLENECK ISSUE FOR THIS PLANNED TRIAL, THOUGH, IS THE LACK OF A BIOMARKER TO ACCURATELY AND PRE-SYMPTOMATICALLY IDENTIFY SWS PATIENTS WHO ARE AT RISK TO DEVELOP SEIZURE SYMPTOMS BY 2 YEARS OF AGE. THOSE AT-RISK PATIENTS SHOULD BE IDEAL CANDIDATES TO BE INCLUDED IN OUR PLANNED TRIAL. THIS R21 AIMS TO ADDRESS THIS BOTTLENECK BIOMARKER PROBLEM. WE PLAN TO RETROSPECTIVELY BUILD THE LARGEST MULTI-SITE PRESYMPTOMATIC DATABASE FROM CLINICAL DATA IN KKI AND BCH (AIM 1). WE WILL THOROUGHLY EVALUATE TWO CLINICAL AND BRAIN MRI BIOMARKERS TO IDENTIFY AT-RISK PATIENTS PRE-SYMPTOMATICALLY (AIM 2). THE CENTRAL HYPOTHESIS IS THAT SOPHISTICATED FEATURES THAT ARTIFICIAL INTELLIGENCE (AI) ALGORITHMS EXTRACT FROM CLINICAL AND BRAIN MRI COULD SERVE AS A BIOMARKER TO PRE-SYMPTOMATICALLY IDENTIFY SWS PATIENTS AT RISK OF DEVELOPING SEIZURE SYMPTOMS BY 2 YEARS OF AGE. THIS IS THE FIRST AI-POWERED, LARGE-DATASET-DRIVEN RIGOROUS STUDY FOR PRESYMPTOMATIC CLINICAL AND MRI BIOMARKERS FOR THIS RARE DISEASE. SUCH A BIOMARKER WILL BE IMMEDIATELY USED IN OUR PLANNED CLINICAL TRIALS TO EVALUATE LEVETIRACETAM WITH OR WITHOUT LOW-DOSE ASPIRIN FOR PRE-SYMPTOMATIC TREATMENT.
The Children's Hospital Corporation
Project Grant
$750.3k
8/15/22
8/3/23
R03TR004017
EVALUATING THE IMPACT OF BASIC NEEDS ASSESSMENT AND SUPPORT TO IMPROVE COLPOSCOPY SHOW RATE: THE BASICS TRIAL - PROJECT SUMMARY/ABSTRACT EACH YEAR, APPROXIMATELY 3.5 MILLION INDIVIDUALS HAVE AN ABNORMAL CERVICAL SCREENING RESULT AND ARE RECOMMENDED FOR MEDICAL FOLLOW-UP, MOST COMMONLY COLPOSCOPY. COLPOSCOPY ALLOWS HEALTH PROVIDERS TO DETECT PRE-CANCERS AND OFFER THERAPEUTIC INTERVENTIONS THAT MAY PREVENT CERVICAL CANCER. UNFORTUNATELY, BETWEEN 37% AND 77% OF PATIENTS ARE LOST TO FOLLOW-UP AFTER THEIR ABNORMAL SCREEN AND NEVER RECEIVE APPROPRIATE CARE. LOW ADHERENCE TO COLPOSCOPY IS ESPECIALLY PREVALENT AMONG BLACK PATIENTS, THOSE WITH LOW INCOME, AND INDIVIDUALS WHO ARE UNINSURED OR HAVE MEDICAID, LEADING TO SOCIOECONOMIC DISPARITIES IN CERVICAL CANCER INCIDENCE AND MORTALITY. OUR PRELIMINARY DATA FROM TWO UNIVERSITY-BASED COLPOSCOPY CLINICS THAT PROVIDE CARE TO THESE UNDERSERVED PATIENTS, SHOW THAT COLPOSCOPY ADHERENCE IMPROVED FROM 50% TO 83% AFTER IMPLEMENTATION OF A TAILORED PHONE CALL INTERVENTION REMINDING PATIENTS OF THEIR APPOINTMENT AND OFFERING NAVIGATOR ASSISTANCE WITH UNMET SOCIAL NEEDS (E.G. UTILITIES, TRANSPORTATION, FOOD, SHELTER, CLOTHING, SAFETY). THESE PILOT DATA SUGGEST THAT A SOCIAL NEEDS NAVIGATOR PROGRAM IMPROVES COLPOSCOPY ADHERENCE, BUT THE LACK OF RANDOMIZATION LIMITS THE STRENGTH OF OUR CONCLUSIONS. IN THIS PROPOSAL, OUR OBJECTIVE IS TO TEST, AND ASSESS THE READINESS FOR IMPLEMENTATION OF A COLPOSCOPY CLINIC-BASED SOCIAL NEEDS NAVIGATOR PROGRAM FOCUSED ON FIVE SOCIAL DETERMINANTS OF HEALTH: HOUSING/SHELTER, FOOD INSECURITY, PERSONAL AND NEIGHBORHOOD SAFETY, FINANCIAL NEEDS, AND DISTRESS. THIS PROJECT WILL TEST THE HYPOTHESIS THAT THIS EQUITY-FOCUSED, SOCIAL NEEDS NAVIGATOR PROGRAM CAN IMPROVE COLPOSCOPY ADHERENCE AMONG UNDERSERVED PATIENTS. WE WILL PERFORM A RANDOMIZED CONTROLLED TRIAL IN WHICH 72 ELIGIBLE PATIENTS (LOW-INCOME, UNINSURED, OR ON MEDICAID) WHO ARE REFERRED FOR COLPOSCOPY AT WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, ARE ENROLLED AND THEN SCREENED FOR UNMET SOCIAL NEEDS AND DISTRESS. THEY WILL THEN BE RANDOMIZED 1:1 INTO EITHER RECEIVE THE SOCIAL NEEDS NAVIGATOR PROGRAM (N=36) OR ENHANCED USUAL CARE (N=36). IN THE NAVIGATOR ARM, A COMMUNITY HEALTH WORKER WILL PROVIDE FOUR MONTHS OF ASSISTANCE TAILORED TO THEIR NEEDS. IN THE ENHANCED USUAL CARE ARM, PATIENTS WILL BE OFFERED INFORMATION AND REFERRAL TO UNITED WAY 2-1-1, A FREE, 24-HR NATIONAL HELPLINE THAT CONNECTS CALLERS WITH LOCAL RESOURCES. IN SPECIFIC AIM 1 WE WILL DETERMINE THE EFFICACY OF OUR SOCIAL NEEDS NAVIGATOR PROGRAM TO IMPROVE COLPOSCOPY ADHERENCE. AIM 2 WILL ASSESS THE ABILITY OF OUR NAVIGATOR PROGRAM TO REDUCE UNMET SOCIAL NEEDS AND DISTRESS. AIM 3 WILL USE THE RE-AIM FRAMEWORK TO EVALUATE METRICS OF IMPLEMENTATION AND POTENTIAL FOR DISSEMINATION. THE PROPOSED WORK WILL PROVIDE KEY DATA TO LAUNCH A LARGE, PRAGMATIC, MULTISITE RANDOMIZED CONTROLLED TRIAL TO RIGOROUSLY TEST THE EFFECTIVENESS, IMPLEMENTATION, AND MAINTENANCE OF OUR SOCIAL NEEDS NAVIGATOR PROGRAM ACROSS DIFFERENT PATIENT POPULATIONS, COMMUNITY SETTINGS, AND HEALTHCARE ORGANIZATIONS. IF SUCH A TRIAL SHOWS THAT OUR NAVIGATOR PROGRAM IS EFFECTIVE, COST-EFFECTIVE, FEASIBLE, AND ACCEPTABLE, IT CAN BE WIDELY IMPLEMENTED TO IMPROVE COLPOSCOPY ADHERENCE AND EQUITY IN CERVICAL CANCER PREVENTION, INCIDENCE, AND MORTALITY.
The Washington University
Project Grant
$235.3k
7/1/22
7/1/23
UG3AR079297
CLINICAL TRIALS IN A DISH USING A PERSONALIZED MULTI-TISSUE PLATFORM FOR ATOPIC DERMATITIS
The Trustees Of Columbia University In The City Of New York
Cooperative Agreement
$600.0k
9/23/20
3/13/23
Name
Description
Solicitation Number
Federal Agency
Due Date
(Click to sort descending)
Posted Date
(Click to sort descending)
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.
RFA-NS-23-007
Department of Health and Human Services National Institutes of Health
4/4/25
9/15/22
Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
The purpose of this funding opportunity announcement (FOA) is to provide investigators with access to resources provided by the Data Management Coordinating Center for Diagnostic Centers of Excellence (RFA-NS-22-051), as part of the next phase of the Undiagnosed Diseases Network. Resources include infrastructure, data management, and clinical research support for a new Network of clinical sites that provide diagnostic services for patients with undiagnosed diseases.
PAR-23-171
Department of Health and Human Services National Institutes of Health
5/15/25
4/6/23
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
The National Institutes of Health (NIH) is seeking applications for the NIH Research Conference Grant (R13) to fund high-quality conferences that are relevant to public health and the scientific mission of the participating institutes and centers. Eligible applicants include institutions of higher education, hospitals, governments, and non-profits. The program falls under 24 federal grant programs focused on biomedical research covering areas such as cancer, diabetes, mental health, neuroscience, and more. The R13 grants support conferences to advance knowledge and collaborations in these and other health-related fields. Review of applications is ongoing through multiple receipt dates each fiscal year. Recent grant awards under this program have ranged from approximately $35,000 to over $6 million, with typical project durations spanning 2-5 years. The research activities are expected to be conducted at the recipient organizations' facilities across the United States.
PA-24-141
Department of Health and Human Services National Institutes of Health
10/7/24
3/7/24
Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.
PAR-19-220
Department of Health and Human Services National Institutes of Health
2/16/22
3/13/19
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations.
RFA-HL-23-008
Department of Health and Human Services National Institutes of Health
2/28/24
11/16/21